B rain metastases are the most common intracranial tumors, 12, 31 and the burden of this challenging disease appears to be increasing, due to longer survival of patients with metastatic cancer as well as better detection. Use of WBRT alone has resulted in patient survival of approximately half a year in prospective studies, and palliation of neurological symptoms or improvement in functional status is observed in less than half of all treated patients. 2, 6, 17, 22, 23 Focal therapy, such as surgery or radiosurgery, in addition to WBRT improves outcomes and prolongs survival in selected patients. 2, 17, 23 The benefit of focal therapy for brain metastases is anticipated to be even greater for malignancies that have traditionally been viewed as radioresistant, such as melanoma, RCC, and sarcoma, which may not respond well to fractionated WBRT. Data from the Surveillance, Epidemiology, and End Results (SEER) program 26 show that the incidence of melanoma and RCC have increased from 7.9 and 7.1 per 100,000 patients, respectively, in 1975 to 21.5 and 13.4 per 100,000 patients, respectively, in 2005. With the advent and anticipation of more effective therapies for extracranial metastatic disease, controlling brain Object. The purpose of this study was to examine the results of using Gamma Knife surgery (GKS) for brain metastases from classically radioresistant malignancies.
metastases will remain a critical challenge. The purpose of this research was to examine the effectiveness of our strategy using GKS with or without WBRT in this patient population over a 9-year period.
Methods
All patients with brain metastases from melanoma, RCC, and sarcoma who underwent GKS at the State University of New York Upstate Medical University were included in this retrospective review. The project was evaluated by the local institutional review board, and deemed to be exempt from full review. The series includes patients who underwent GKS between August 1998 and July 2007. Data were obtained from patient medical charts, and all available radiographic studies were reviewed along with official reports. Survival data were augmented from the Social Security Death Index.
Information was available regarding patient and disease characteristics including demographics, performance status, histology, number and size of treated metastases, and status of extracranial disease. Treatment-related data that were recorded included therapies in addition to GKS (surgery, systemic therapy, and WBRT), as well as GKS margin dose, prescription isodose, maximum dose, and percentage of coverage. Patients were followed clinically at 1 month after GKS and every 3 months thereafter. Magnetic resonance imaging of the brain was obtained at least every 3 months or as clinically indicated by symptoms. Overall survival was measured from the time of GKS until death or most recent follow-up and also from the onset of brain metastases. Cause of death was recorded when available. Local control of individual lesions was assessed radiographically in the context of clinical data. Lesion progression was scored as a 25% increase in size of the maximum diameter unless further follow-up revealed subsequent decrease to or below baseline size without further central nervous system-directed therapy. If an individual lesion required resection following GKS, local progression was scored regardless of size or pathology of the specimen (tumor vs necrosis). Distant withinbrain failure was defined as new metastases outside the treated GKS volume. Any progression, either local or distant within-brain recurrence, was evaluated as overall within-brain control.
Statistical analysis was performed using a commercially available software package. Actuarial overall survival, freedom from local progression, and freedom from distant within-brain failure were calculated using the Kaplan-Meier method 16 with the log-rank test used to compare groups. Cox regression 9 was used to identify associations between these outcomes and various patient-, disease-, and treatment-related factors. A probability value < 0.05 was considered statistically significant.
Seventy-six patients were identified as having melanoma (50 patients), RCC (23 patients), or sarcoma (3 patients). Ninety-seven GKS procedures were performed in these patients to treat 303 metastases. Patient characteristics are shown in Table 1 . The median KPS score at the time of GKS was 80 (range 20-100). Sixty-two patients (81.6%) had uncontrolled extracranial disease either at the primary or metastatic site. The majority of patients (60, 78.9%) were in RPA Class 2. Gamma Knife surgery was delivered to a mean of 3.97 brain metastases per patient (range ). The median GKS dose delivered to the tumor margin was 18 Gy (range 8-30 Gy). The median isodose prescription to the tumor margin was 50% (range 35-85%). Thirty-seven patients (48.7%) had WBRT as part of their treatment, and 18 of these patients (23.7%) completed WBRT prior to GKS. The median WBRT dose was 3000 cGy, typically in 10 fractions. Thirty-eight neurosurgical operations were performed in 30 patients (39.5%).
Results

Overall Patient Survival
The median follow-up for all patients was 4.9 months, and 69 patients (89.6%) died. The median overall survival of all patients was 5.1 months from the time of the first GKS and 8.4 months since the discovery of brain metastases. Univariate analysis revealed that KPS score (p = 0.000004), RPA class (p = 0.00043), and single metastases (p = 0.028) were the factors most predictive of overall patient survival. There was no relationship between survival and sex, age, histology, number of metastases (treated as a continuous variable), extracranial disease status, or WBRT. Cox regression analysis revealed only KPS score to be a significant prognostic factor for overall patient survival in multivariate analyses ( Table 2) . For patients with a KPS score ≥ 70, median overall survival was 7.1 versus 1.3 months for patients with a KPS score ≤ 60 (p = 0.013). Figure 1 shows Kaplan-Meier actuarial overall survival curves for patients with favorable and unfavorable KPS scores. When survival following GKS procedures for patients with 1-3 brain metastases was compared with patients with 4 or more lesions, no statistically significant difference was noted.
Local Control of Individual Lesions
Data on local lesion control were available for 250 (82.5%) of the 303 lesions treated. The actuarial 12-month rate of freedom from local progression for individual lesions was 77.7%. Local control was significantly higher for RCC compared with melanoma (93.6 vs 63.0%; p = 0.001) as demonstrated in Fig. 2 . When the analysis was limited to treatment-related factors, the percentage coverage of prescribed dose to target volume was associated with local control. The 12-month actuarial rate of freedom from local progression was 71.4% for lesions receiving ≥ 90% coverage versus 0.0% for lesions receiving < 90% (p = 0.00048).
Distant Within-Brain Failure and Overall Within-Brain Control
Data on the appearance of new metastases outside the volume treated with GKS were available for 75 (77.3%) of 97 GKS procedures. Using the Kaplan-Meier meth-od, the median time to distant within-brain failure was 6 months. The actuarial 12-month rate of freedom from distant within-brain failure was 37.3%. According to the multivariate analysis, histology and the presence of 3 or fewer metastases were associated with distant withinbrain control.
The median duration of freedom from any withinbrain failure, defined as either local recurrence or new metastases, was 4.2 months from the time of GKS. The 12-month actuarial rate of freedom from any withinbrain progression was 25.9%. Patient age, histology, repeat GKS, single metastasis, 3 or fewer metastases, and WBRT prior to GKS were found to be significantly associated with overall within-brain control.
Discussion
The benefit of focal therapy directed at individual brain metastases in addition to the use of WBRT is well established. Patchell et al. 23 demonstrated a benefit of the addition of surgery to WBRT for patients with single metastases in a randomized trial with 48 patients. Patient survival was improved, ranging from 15 weeks for WBRT alone to 40 weeks with metastectomy and WBRT (p < 0.01). Of note, functional independence, scored as duration with a KPS score ≥ 70, was much longer in patients who underwent surgery (8 vs 38 weeks). Although the complications of treatment in this study were similar between groups and overall quite reasonable, many patients in clinical practice are not reasonable surgical candidates. For many of these patients, radiosurgery can provide similar benefits to craniotomy with less risk.
Although the RTOG protocol 9508 2 was a negative trial overall with regard to the primary endpoint (survival), it did firmly establish radiosurgery as a treatment option for brain metastases. Three hundred three patients with 1-3 newly diagnosed brain metastases were randomized to receive either WBRT alone or WBRT followed by radiosurgery within a week, with either linear accelerator-based radiosurgery or GKS. Survival was superior with the addition of radiosurgery in the subset of patients with single metastases, 4.9 compared with 6.5 months (p = 0.0393). A multivariate analysis demonstrated that patients with RPA Class 1 and either squamous cell carcinoma or non-small cell carcinoma also had improved survival with the addition of radiosurgery. At 1 year, local control was achieved in 82% of metastases using WBRT in addition to radiosurgery. Additionally, in terms of quality of life, radiosurgery led to better preservation of KPS score at 6 months as well as decreased steroid use. In relation to our current data regarding radioresistant metastases, it is noteworthy that only 4% and 3% of patients in RTOG protocol 9508 had melanoma and RCC, respectively.
With the growing availability of radiosurgery and increasing evidence of its ability to achieve high rates of local tumor control, investigators have questioned the need for WBRT in selected patients. Sneed and colleagues 29 presented retrospective multiinstitutional data showing that radiosurgery followed by close observation and aggressive salvage allows omission of WBRT without decreasing survival. This strategy avoids the risk of toxicity from cranial radiation, particularly late complications, and has thus been advocated for patients with favorable prognostic factors. For example, Hasegawa and associates 15 reported on 172 patients with brain metastases who were treated initially without WBRT. Median patient survival in this study was 8 months and local control was achieved in 87% of treated lesions. Although the actuarial intracranial control rate was only 43% at 1 year, 78.3% of deaths were due to extracranial disease. The authors concluded that WBRT should not be part of the initial treatment for patients with long predicted survival, specifically those with 1 or 2 tumors, good control of their primary cancer, better KPS scores, and younger age. Probably because of the belief that WBRT is particularly ineffective for patients with radioresistant histologies, a significant number of patients in this series had melanoma (21.5%) or RCC (18%). Local control was worse for these 2 groups, 77% and 79%, respectively, and melanoma was found to be a significant predictor of worse survival in multivariate analyses.
The omission or delay of WBRT in certain patients has This multiinstitutional comparison of WBRT as well as radiosurgery versus radiosurgery alone included 132 patients with 1-4 brain metastases. The primary endpoint, overall survival, did not differ between treatment groups, confirming the basic premise of the strategy. On the other hand, statistically significant differences were identified for brain tumor recurrence (local or distant), and thus the need for salvage therapy. Patients randomized to receive WBRT had a 12-month actuarial rate of brain tumor recurrence of 46.8% compared with 76.4% without WBRT. This rate difference was the result of improved local control as well as better distant within-brain control with the addition of cranial radiotherapy. A follow-up report 4 of neurocognitive function for patients in this trial demonstrated a complex relationship between treatment group and Mini-Mental State Examination score. The improvement observed in control of brain metastases for patients receiving WBRT led to better neurological function early on compared with patients who underwent radiosurgery alone. There was a significantly shorter average duration until neurological deterioration in this study: 7.6 months without WBRT versus 16.5 months with the combination treatment (p = 0.05). These observations are consistent with results from Regine et al., 25 who found that 71% of patients who developed recurrence after radiosurgery alone were symptomatic and 59% had an associated neurological deficit. On the other hand, with further followup, the negative impact of cranial radiotherapy became evident in long-term survivors as a continuous decline in Mini-Mental State Examination score over time, whereas the trend in the radiosurgery alone arm was for stabilization of neurocognitive function after the early decline. With the observation that the duration to adverse effects from WBRT is much longer than the median survival for patients with brain metastases, the authors emphasized the relationship between WBRT, improved disease control, and better early neurocognitive function.
The debate regarding the roles of radiosurgery and WBRT in the management of patients with brain metastases is complex, and adding consideration for radiobiology based on tumor type appears to be important. The classical radioresistance of melanoma, RCC, and sarcoma has led to particular enthusiasm for radiosurgery in these patients as well as interest in omission of WBRT. Retrospective data, including our own, suggest no difference in survival in this patient population with or without cranial radiotherapy, 7, 13, 14, 20, 21, 27 and most of these reports deemphasize the role of WBRT accordingly. Interestingly, the sole prospective report, a Phase II trial of radiosurgery alone for patients with 1-3 brain metastases from melanoma, RCC, or sarcoma, cautions against the omission of cranial radiation. 18 The 36 patients enrolled had a median survival of 8.3 months. The primary endpoints, 3-and 6-month intracranial progression, were 25.8 and 48.3%, respectively. Recurrences were approximately evenly divided between local progression and distant within-brain failure. Only this type of prospective data are likely to add significantly to the debate regarding WBRT for radioresistant tumors, and practitioners will continue to individualize management of these patients based on established prognostic factors.
In various reports, a number of such factors have been identified that are predictive of outcomes in patients with brain metastases. Recursive partitioning analysis, 10 based on patient age, KPS score, and extracranial disease status, is perhaps the most frequently cited factor. The extent of brain metastases has also been indicated as a prognostic factor. In an early RTOG study, Swift 30 found that, in 779 patients in a randomized trial of misonidazole with radiation therapy, the presence of 3 or fewer brain metastases was the only prognostic factor associated with improved survival. Because of data such as this, the number of metastases present has been a frequent selection criterion for subsequent trials, leading to a relative lack of information regarding outcomes in patients with multiple metastases. Although patients with a single metastasis are known to have more favorable outcomes than those with 2 or more metastases, 10, 11 there is growing data regarding the use of radiosurgery in patients with multiple metastases, perhaps defined as 4 or 5 metastases and higher. For example, Bhatnagar et al. 5 reported retrospectively on 205 patients with 4 or more brain metastases who underwent GKS with or without WBRT. Median patient survival was 8 months, leading the authors to suggest that radiosurgery is an appropriate treatment for certain patients with multiple metastases. Likewise, Pollock et al. 24 reported on 52 patients treated with radiosurgery for a median of 3 brain metastases per patient from a variety of primary sites. Median overall survival was 15.5 months for all patients and 8 months for patients with RPA Class 3. These impressive results led these investigators to conclude that aggressive treatment including radiosurgery is appropriate in selected patients with multiple metastases. In contrast, Amendola and colleagues 1 found a median survival of only 4.3 months in 72 patients treated with GKS for 10 or more metastases. They concluded that radiosurgery may even be useful in these patients, although it seems likely that there is some upper limit to the benefit of this approach.
In patients with radioresistant brain metastases, the rationale to consider radiosurgery in patients with multiple lesions is perhaps stronger, as WBRT is anticipated to have less effect. Although the number of patients with radioresistant histologies in the previously noted studies is small, other patient series do address this population. Wowra and associates 32 have reported on their experience using GKS for the treatment of patients with multiple brain metastases from RCC. These investigators treated 350 lesions in 75 patients, with a median patient survival of 11.1 months. No difference in survival was noted between patients with 3 or fewer metastases compared with patients with more than 3. In the series of patients with brain metastases from melanoma treated using GKS published by Mathieu et al., 19 61 (25%) of 244 patients received treatment to 4 or more lesions. The median survival of the patients in this study for the entire group was 5.3 months, and patients with single lesions had significantly longer survival than patients with > 1 metastasis. These authors suggested that patients with as many as 6 metastases may benefit from radiosurgery.
We have adopted an aggressive management strategy for brain metastases, particularly from radioresistant primaries, which has led us to consider using GKS with or without WBRT in selected patients with multiple metastases. Table 3 provides a comparison of our selection criteria and outcomes with several other studies. The median patient survival in our series, 5.1 months from the time of GKS and 8.4 months from the discovery of brain metastases, is on the low end of the range of reported values. However, our data suggest that the main reason for this survival duration is not multiple metastases, but the significant number of patients in RPA Class 3 in the series (18.4%). Overall survival from the time of GKS was 7.1 months in the group with a KPS score ≥ 70, despite the fact that there remained an average of 3.9 metastases per patient in this group. We did not identify a statistically significant difference in patient survival following GKS for those with 3 or fewer brain metastases compared with 4 or more. Potential reasons as to why patients with multiple radioresistant brain metastases may benefit from radiosurgery include improvements in systemic disease control (more so with RCC than melanoma, to date) as well as high-resolution imaging to detect smaller metastases, and more aggressive surgical treatment.
Several reports have identified worse outcomes with radiosurgery for melanoma metastases compared with other histologies including RCC. Brown et al. 7 reported on 41 patients with radioresistant brain metastases treated with GKS for 83 lesions. Patients with melanoma had a median survival of 9.7 months compared with 17.8 months for RCC, although this trend was not statistically significant (p = 0.12). Interestingly, actuarial local control was excellent, 95% at 6 months and 86% at 1 year, and did not differ by histological type. These results are somewhat in contrast to results published by Chang et al. 8 for treatment of 189 patients with 264 radioresistant brain metastases using linear accelerator-based radiosurgery. Using this large sample, these investigators were able to identify significantly worse survival and local control of individual lesions in patients with melanoma compared with patients with RCC. The authors concluded that inferior local control allowed progression of intracranial disease to "cause most of the deaths that occur among these patients." 8 On the other hand, some authors have reported excellent local control treating melanoma, using radiosurgery. For example, Mori et al. 20 reported 90% local control, and only 7% of patients died with radiosurgically managed tumors. Similarly, Grob and colleagues 14 reported local control of melanoma metastases as 98.2% at 3 months. Our results are more consistent with the former reports than the latter. We found local control to be significantly higher for RCC compared with melanoma (93.6 vs 63.0%, p = 0.001), although no statistically significant difference in survival was observed.
In addition, the findings in our study suggest some influence of treatment technique on outcome. We were able to find a correlation between target coverage and local control for all metastases treated with GKS in this series. Lesions in which the prescription dose coverage of the target was < 90% had a 12-month actuarial rate of freedom from local progression of 0.0% compared with 71.4% for lesions receiving coverage of 90% or better. Drawing any conclusion from this finding is difficult due to confounding factors such as lesion size and prescription dose, although it makes sense that some relationship between coverage and local control could exist.
Conclusions
Gamma Knife surgery is an effective treatment option for patients with radioresistant brain metastases. In this setting, the KPS score appears to be a more significant predictor of survival than having > 3 metastases. Higher rates of local tumor control were achieved for RCC in comparison with melanoma, and this may have an effect on survival in some patients. Although patient outcomes generally remained poor in this study population, our results suggest that GKS can be considered for many patients with radioresistant brain metastases, even if they have multiple lesions.
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